NEW YORK – Castle Biosciences said Friday that the Veterans Health Administration has expanded its US Federal Supply Schedule contract to include coverage for all of the company’s skin cancer tests, effective April 15.
The initial five-year contract, inked last August, was for a single test, Castle's DecisionDx-Melanoma. Under the expanded agreement, four more tests — DecisionDx-SCC, DiffDx-Melanoma, MyPath Melanoma, and DecisionDx-CMSeq — are now included.
The contract provides access to these tests for veterans being treated through the VHA as well as active-duty service members and their families seeking medical treatment through the Military Health System.
"We are proud that veterans and their families … will now have greater access to our skin cancer tests and the clinically actionable information they provide, which can help guide and improve the management of their disease," Castle President and CEO Derek Maetzold said in a statement.
Financial terms of the contract were not disclosed.